Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2017-02-22 Report Publication Anno…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Immediate Report
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, 'Attached hereto is a report on *Registered Direct Offering Documents* *XTL_6_K_220217_isa.pdf*'. This structure—a brief regulatory filing announcing the attachment or publication of a more substantial document—fits the definition of a Report Publication Announcement (RPA). Although it mentions '6-K' in the filename, the filing itself is the announcement mechanism, not the full 6-K document. Given the short length (1804 chars) and the explicit mention of an attached document, RPA is the most appropriate classification based on Rule 2.
2017-02-22 English
Immediate Report
Capital/Financing Update Classification · 98% confidence The document text explicitly identifies itself as a "Prospectus Supplement" dated February 21, 2017, relating to the offering of American Depositary Shares (ADSs) under a shelf registration statement filed with the SEC (Form F-3 is referenced). It details the offering price, placement agent fees, use of proceeds, and includes a table of contents for both the supplement and the accompanying prospectus. This structure and content are characteristic of a document used to solicit investment for a securities offering, which falls under the category of offering materials. Among the provided codes, 'CAP' (Capital/Financing Update) is the most appropriate fit as this document is fundamentally about raising capital through a securities offering. While it is a prospectus, which is a detailed disclosure document, it is not a periodic report (10-K, IR) or a general announcement (RPA/RNS). It is a specific document detailing a capital raise.
2017-02-22 English
Immediate Report
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. It explicitly states: 'Attached hereto is a report on *Prospectus Supplement Pursuant to Rule 424(b)(5)*' followed by a PDF filename. This structure indicates that the current document is an announcement *about* the publication of another document (a Prospectus Supplement, which is a type of offering/financing document). Since the text is short and serves primarily to announce the availability of an attached/linked report, it fits the definition of a Report Publication Announcement (RPA). While it relates to capital markets, the specific action described is the publication announcement, not the financing details themselves (which would lean towards CAP). Given the 'MENU VS MEAL' rule, RPA is the most appropriate classification.
2017-02-22 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It details a securities purchase agreement for issuing American Depositary Shares and related warrants, including terms of the offering, placement agent agreements, and legal opinions. The content focuses on a financing transaction and capital raising activity. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a call transcript, management report, or governance information. It is a regulatory filing reporting a capital raising event. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (8833 characters) and detailed transaction description support this classification with high confidence.
2017-02-22 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering by XTL Biopharmaceuticals Ltd. It details the offering of ordinary shares represented by American Depositary Shares (ADSs), including pricing, use of proceeds, risk factors, and legal disclaimers. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, management discussion, or any other type of report listed in the filing definitions. It clearly relates to financing activities and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full prospectus supplement, not just an announcement or regulatory filing. Confidence is high due to explicit references to securities offering, placement agent fees, and registration statement details.
2017-02-22 English
Immediate Report
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Form 6-K" and is identified as a "Report of Foreign Private Issuer" filed with the SEC. Form 6-K is used by foreign private issuers to report material information not required to be reported under home country regulations or to the stock exchange. The content details a financing event: an announcement of entering into definitive agreements for a registered direct offering of securities (ADSs and warrants) for gross proceeds of $2.5 million. This type of material event disclosure, filed on Form 6-K, does not fit neatly into the specific categories like 10-K (Annual Report), ER (Earnings Release), or CAP (Capital/Financing Update, which usually refers to a broader update or prospectus, not the specific 6-K filing itself). Since Form 6-K is a general, periodic, or event-driven filing for foreign private issuers that doesn't match the other specific definitions (like AGM-R, DEF 14A, etc.), the most appropriate fallback category is Regulatory Filings (RNS).
2017-02-19 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.